PrCSCs obtained directly from prostate cancer patients, prior to expansion in tissue culture, express CD90, CD73, and CD105 in the absence of CD14, CD20, CD34, CD45, and HLA-DR as demonstrated using an optimized flow cytometry assay (Figure 3, Table 2). Here, NT5E is linked to prostate carcinoma.